Blog

On Belief

Mike Irwin featured image with background

From Management Style to Strategic Discipline 

As recently as ten years ago, I might not have been able to define my management style precisely.  What I think I understood, however, was what consistently drove results: conviction behind strong ideas, clarity about why they mattered, and disciplined execution.  Early in my career, two questions became central to how I evaluated strategy: So what?  Why does it matter?  Those questions still guide me.  Insight alone does not create value, though.  Value is created when insight becomes action that matters in the market. 

I also learned very early on that discipline matters.  Have a plan and work to the plan.  But planning without conviction is rarely enough.  If leaders cannot clearly explain why their offering matters, organizations can become efficient at work that does not truly differentiate the business.  The strongest companies pair discipline with a shared belief in what they do and why it matters to customers.  That belief is not abstract culture.  It is a strategic asset. 

When teams genuinely understand the value they represent, they operate differently and better.  They communicate with greater clarity and engage scrutiny with confidence.  They make better decisions about where to focus.  Customers, partners, and investors notice the difference. 

What Olink and Metabolon Reveal About Conviction and Market Relevance 

I saw these correlates clearly at Olink.  During its initial U.S. expansion, leadership expected teams not just to know the product but to understand the science, the customer value, and the platform’s importance well enough to represent it with authority.  That standard created alignment, and over time, that alignment helped build commercial traction and market credibility.  The lesson was simple: when conviction is grounded in substance, it strengthens execution. 

I see a similar pattern at Metabolon.  Like many life sciences companies, Metabolon faced challenges in 2024.  Leadership transitions, organizational change, and market pressure tested the business.  At the same time, metabolomics often received less attention than genomics or proteomics and was still sometimes viewed as specialized rather than essential. 

Our understanding of why and how the business matters is changing, however.  We see Metabolites as not merely correlated or associated signals.  They are direct observations of biological events that have occurred.  In a multiomics landscape, that distinction is important.  Metabolomics substantiates biological hypotheses in a determinate fashion, challenges assumptions from upstream data, and reveals biology that other approaches may miss. 

That understanding is strengthening our commercial foundation.  Rather than relying on broad positioning, we can focus on evidence and demonstrated results.  This focus helps us clarify where we have the strongest right to win and sharpens our go-to-market execution.  It even drives part of our strategy to invest heavily in bioinformatics solutions that are helping to revolutionize the relationships between various ‘omics. 

Why Belief Creates Better Strategy, Execution, and Long-Term Value 

These corollaries also matter to investors.  In life sciences, scientific differentiation alone is not enough.  Value is created when scientific credibility is translated into market relevance and commercial discipline.  The companies that outperform are usually the ones that align both.  Belief, in that context, is not separate from discipline.  It is what makes discipline more effective. 

That is why belief matters more than many leaders acknowledge.  Properly understood, it is not optimism detached from evidence.  It is a clear connection between understanding and action.  It helps organizations move with confidence and sustain execution through uncertainty. 

For CEOs, CFOs, and investors, these are not soft ideas.  They have practical consequences.  Organizations with genuine conviction around their value proposition tend to make better strategic choices.  They pursue clearer priorities and build stronger trust with customers and investors. 

In life sciences, where innovation cycles are long and adoption must be earned, that combination matters.  Companies that understand their relevance are better positioned to adapt and execute with discipline.  That is how durable value is created.  Belief is not the whole of leadership, but it is one of its most important accelerants.  When belief is authentic and grounded in evidence, it sharpens strategy and strengthens execution. 

Michael Irwin
Michael Irwin, Vice President, Global Head of Sales at Metabolon, is a seasoned sales leader with 30 years of experience in commercial roles and leading teams to achieve high revenue growth in competitive and complex markets.

Topics

Share this article

GET STARTED

Talk with an expert

Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.

Find us on:

Talk with a Metabolomics expert

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.